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Abstract
Introduction: Nasopharyngeal carcinoma among the children has been rare accounting for only 1% of all pediatric malignancies.
Both genetic and environmental factors have contributed to the development of nasopharyngeal carcinoma. Among the children
there was a higher rate of undifferentiated histology. The mean age of nasopharyngeal carcinoma diagnosis has been 11 years old age;
and the most common site was nasopharynx. Palpable lymphadenopathy, dysphasia and neural defect were common associated
signs.
Case Presentation: A 15-year-old boy has presented with a mass that located near by the heart in the left side of mediastinum with
invasion to anterior mediastinum from two years ago. In biopsy, nasopharyngeal carcinoma, non-keratinizing type, has diagnosed
while there was no involvement of nasopharyngeal region. Patient has treated by 70 Gy (2.0 Gy/fraction) radiotherapy plus concomi-
tant chemotherapy with base of docetaxel. But the mass had no regression. Then, the patient has treated with Cisplatin 100 mg/m2
IV on days 1, 22, and 43 with radiation, then cisplatin 80 mg/m2 IV on day 1 plus fluorouracil (5-FU) 1000 mg/m2/day by continuous IV
infusion on days 1 - 4 every 4wk for 3 cycles and after remission interferon beta has added to treatment for 6 months duration as a
maintenance therapy. After 1 year follow up; the patient was in complete remission. In the course of therapy, only hypothyroidism
has occurred.
Conclusions: Nasopharyngeal carcinoma in childhood, without nasopharyngeal involvement, initially could be detected in other
sites such as pericardium. Also good results could be respected by cisplatin and 5-fluorouracil based neoadjuvant chemotherapy
before radiotherapy plus interferon beta as a maintenance therapy in childhood aggressive nasopharyngeal carcinoma.
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1. Introduction
Nasopharyngeal carcinoma lymphoepithelioma has
been very rare among the children. Only 3% of all nasopha-
ryngeal carcinoma cases havee observed among the chil-
dren less than 19 years which make up to 1% of all child-
hood cancers (1-3). Nasopharyngeal carcinoma (NPC) has
known as a malignancy of the postnasal space. This cancer
was highly prevalent in southeast China, with an incidence
varying between 30 and 80 cases per 100,000 per year, and
among Eskimos, with an incidence of 25 cases per 100,000
per year. An intermediate incidence of NPC has found in
the Mediterranean basin and among Arabic populations
from North Africa [8 – 12 cases per 100,000 per year com-
pared with, 1 case per 100,000 per year in Western coun-
tries]. It has suggested that the Geographic and genetic fac-
tors may also play a role in its occurrence. Some studies
in Asia and Mediterranean region or basin have suggested
a relation between salted fish and meat with nasopha-
ryngeal carcinoma incidence due to releasing volatile ni-
trosamines during cooking (1). In addition, nasopharyn-
geal carcinoma has associated with specific HLA (human
leukocyte antigen) alleles such as B17, BW46, AW19, Bsinz,
and A2. Epstein-Barr virus (EBV), alcohol and tobacco have
also been risk factors for nasopharyngeal carcinoma (1-4).
So far, the world health organization has introduced three
histological types of nasopharyngeal carcinoma. Type I:
Keratinizing squamous cell carcinoma which has associ-
ated with EBV infection, and alcohol and tobacco consump-
tion. Type II: Non-keratinizing epidermoid carcinoma.
Type III: lymphoepithelioma which has been an undifferen-
tiated carcinoma. Almost all nasopharyngeal carcinomas
in children were type III (4). NPC was more common in
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males. The mean age of occurrence is 13 years old and the
most common involved site is Rosen- muller’s fossa. It has
frequently presented as a painless upper neck mass which
has associated with palpable cervical lymphadenopathy.
Tumor infiltration could cause hearing loss, tinnitus, nasal
obstruction, epistaxis and dysphagia. Cranial nerve XII and
VII involvement might cause diplopia. Other symptoms
might include vision disturbances, Ageusia and flaccidity
of shoulder. The most common sites of distant metas-
tases were lungs, bones, mediastinum, bone marrow, and
visceral organs. Paraneoplastic symptoms such as hyper-
trophic osteoarthropathy (HOA), dermatomyositis (DM),
and inappropriate antidiuretic hormone secretion have
seen in advanced cases. Differential diagnoses have com-
monly included Rhabdomyosarcoma and lymphoma. an-
giofibroma was the most common benign tumor of the
nasopharynx (1-4). Because of its rarity in children, the
diagnosis has often delayed, and most patients have pre-
sented at advanced stage (III or IV) of the disease. More-
over NPC treatment guidelines were controversial (2). Sero-
logical evidence of EBV infection has seen mostly in pa-
tients. Circulating EBV DNA analysis has helped to eval-
uate the response to treatment and relapse (5). Patients
with metastatic disease at diagnosis had a poor progno-
sis. Although, it has not associated with size of the mass
(6). The most important prognostic factor was pathologi-
cal subtype and early response to treatment (2). Radiother-
apy has remained the main treatment modality for NPC.
Limited involvement of the nasopharynx with or without
extension to parapharyngeal space (T1, T2) could be treated
with radiotherapy 65 to 70 Gy. These regions were inacces-
sible for surgery (1-3, 7). NPC was a very sensitive tumor to
chemotherapy. Neoadjuvant therapy followed by local ra-
diation therapy; has improved the prognosis of children
with advanced disease (1, 3, 7). Neoadjuvant chemother-
apy could diminish margin of tumour and destroy hid-
den metastases, which ameliorate survival (8).Cisplatin,
methotrexate (MTX), leucovorin (LV), fluorouracil (5-FU)
has used more frequently and have associated with event-
free survival rates (EFS) of 77% at 4 year (7). Neoadjuvant
chemotherapy in children has carried less risk and yields
better outcomes due to limiting the dose of radiation (6).
2. Case Presentation
A 15-year-old patient with a history of chest pain and
a left sternal mass over two years ago has referred to our
medical center.Within a few weeks, mediastinal mass pro-
gressed quickly. The patient’s CT scan has revealed a soft tis-
sue mass adjacent to the heart and the left side of anterior
mediastinum (Figure 1). In addition, a small mass attached
to the posterior wall of the left diaphragm has seen in the
lung parenchyma. The patient had no pleural effusion. It
has also shown the lack of involvement of the nasopharynx
on serial MRI and CT scans (Figure 2).
Figure 1. Mediastinal Windows of CT-Scan Before Chemotherapy
Figure 2. The Contrast CT Scan Indicated No Involvement of the Nasopharynx Before
Starting Chemotherapy
The patient underwent nasopharyngoscopy as well as
biopsy from multiple regions. Pathologic evaluation has
revealed lymphoid hyperplasia and chronic inflammatory
changes with no evidence of neoplastic tissue. The patient
had no cerebral, abdominal or bone marrow involvement.
The patient received 70 Gy (2.0 Gy/fraction) radiother-
apy in 27 sessions and chemotherapy with Taxotere for two
sessions. The tumor size shrunk initially but grew back af-
ter one month, causing chest pain and shortness of breath
in patient. The biopsy sample taken from mass has re-
assessed pathologically. The examinations have revealed
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multiple clusters of metastatic cells with vesicular nuclei
and prominent nucleoli as well as median amount of non-
keratinizing cytoplasm. The Non-keratinizing type (WHO
type II) of nasopharyngeal carcinoma has confirmed (Fig-
ure 3). EBV RNA s markers have definite it. The patient
has received new chemotherapy protocol of Cisplatin 100
mg/m2 intravenous on days 1, 22, and 43 accompanied with
radiation, then cisplatin 80 mg/m2 intravenous (IV) on day
1 plus fluorouracil (5-FU) 1000 mg/m2/day by continuous
intravenous infusion on days 1 - 4 every 4weeks for 3 cy-
cles. After the second cycle, the mass has fully resolved in
CT scan (Figure 4). Upon completion of the third cycle, the
patient has received Interferon beta 105µg/kg/SQ 3 times a
week for 6 months as additive therapy. During the mainte-
nance therapy blisters have emerged on the patient’s face
which have controlled with Clindamycin. Furthermore,
three months after completion of the treatment, the pa-
tient has developed hypothyroidism with a TSH of 21.27 and
underwent treatment with Levothyroxine. After one year
of follow- up, the patient was in complete remission and
had no particular complaint and was fine with heavy phys-
ical exercises. It hasn’t given him shortness of breath or
other signs anymore. CT scan of the neck, chest, and na-
sopharynx, in addition to abdominal sonography hasn’t
shown any sign of relapse.
Figure 3. Histopathological Analysis of the Mass Resected
3. Discussion
Nasopharyngeal carcinoma has been rare among chil-
dren accounting for 1-3% of all pediatric malignancies and
20 - 50% of all primary tumors in this age group. More-
over it has often presented in advanced stage (2). Our case
Figure 4. CT Scan of The Mediastina. Post-Chemotherapy Follow-Up of Previously
Diagnosed Tumor
Table 1 . IHC Study from Specimen
Variable Condition
CD20 positive in lymphoid cells
CD3 positive in lymphoid cells
Cytokeratin positive in epithelial cell
CEA negative
Thyroglobulin negative
EMA positive
CK positive
LCA negative
Ki 67 positive
Table 2. Laboratory from the First Hospitalization
Variable Condition
EBV-VCA IgG 243 (positive)
EBV-VCA IgM < 10 (negative)
Alpha-Fetoprotein 2.4
Beta HCG negative
ESR 68
CBC normal
LFT normal
ALP normal
LDH normal
was a 15 year-old male patient with nasopharyngeal carci-
noma on the left side of the heart. Age, sex, geographic lo-
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cation and severity were identical to other reports while
the site was ectopic. nasopharynx and neck were the most
common primary site of Nasopharyngeal carcinoma. Al-
though in this case no cervical involvement has found nei-
ther initially nor in the development of the disease (1-3).
Lymphoepithelioma (WHO type III) has reported as the
most common type of nasopharyngeal carcinoma in chil-
dren. Our patient has diagnosed as non-keratinizing epi-
dermoid (WHO type II) (9). This type of pathology was
uncommon and had poorer response to treatment than
Type III (2). Investigating EBV-VCA IgG In our patient has
revealed strongly positive EBV infection. The result has
confirmed the association of EBV in causing nasopharyn-
geal carcinoma (NPC), especially in non-keratinized type as
other studies have highlighted as well (1, 2, 4, 5). The pa-
tient has not responded to the Initial radiotherapy. Thus,
cisplatin-based chemotherapy administered to the patient
and subsequently was followed by remission. Then, over
the 6 months period, Patients received interferon as main-
tenance therapy. During one-year follow-up, the patient
has sustained complete remission. The only complication
was radiation-induced hypothyroidism. Response to treat-
ment has caused enhanced recovery, reducing tumor size,
and subsequently reducing radiation fields and dosage,
hence it could reduce adverse effects of treatment partic-
ularly advanced stages, and type II (2, 6, 10).
3.1. Conclusions
Primary Nasopharyngeal carcinoma in children could
occur in ectopic locations (e.g. around the heart). Early di-
agnosis has played an important role in the prognosis of
the patient. Cisplatin-based Neoadjuvant chemotherapy, 5-
fluorouracil (5-FU) and supportive therapy with interferon
beta have appeared to be effective in the treatment of chil-
dren with advanced NPC.
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